Gossamer Bio
GOSS
88 hedge funds and large institutions have $632M invested in Gossamer Bio in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
11% more funds holding
Funds holding: 79 → 88 (+9)
1.5% less ownership
Funds ownership: 62.7% → 61.2% (-1.5%)
9% less capital invested
Capital invested by funds: $694M → $632M (-$62M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
91% less call options, than puts
Call options by funds: $1.53M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 2 |
BlackRock
New York
|
+$15M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.04M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$7.22M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.8M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
-$15.9M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$8.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.58M |
GOSS Hedge Fund Activity: Q4 2019 in Review
88 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2019, worth a combined $632M — down 8.9% from $694M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new GOSS positions and 9 closed out — a net gain of 15 holders — while 30 added to existing stakes and 22 trimmed.
The largest buyer was State Street, adding an estimated $18.1M. The largest seller was Fidelity Investments, cutting an estimated $17.9M.
- 88 institutional investors held Gossamer Bio (GOSS) as of Q4 2019, up from 79 in Q3 2019.
- Funds reported $632M of Gossamer Bio stock for Q4 2019, down 8.9% quarter-over-quarter.
- 24 funds opened new Gossamer Bio positions in Q4 2019 and 9 closed out, a net change of +15 holders.
- The largest Gossamer Bio buyer in Q4 2019 was State Street, an estimated $18.1M added.
- The largest Gossamer Bio seller in Q4 2019 was Fidelity Investments, an estimated $17.9M sold.
Based on aggregated 13F filings for Q4 2019.